Remus Pharmaceuticals Share Price Live

Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a private limited company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat. Subsequently, Company converted from a private company to public company and consequently, the name of Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad. The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs. It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries. The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet. The core business of the Company into three categories, which comprise of Manufacturing, through loan licencse or on contract manufacturing bassis, of approved finished formulations and distribution of the same in various countries; Trading of Active Pharmaceutical Ingredients and Technical Consultancy on preparation of reports on pharmaceutical dossiers.The product portfolio comprises of therapeutic drugs like ACE inhibitors, anaesthetic, Anti histamine, Antifungal, Anti-inflammatory, Antibiotic, Antidiabetic, Antipsychotic, Antiretroviral, Chronic Obstructive Pulmonary Disease, Asthma, Carcinoid tumours, CNS stimulants, Nasal decongestants, Potassium deficiency, Probiotic, Antispasmodic, Ocular-hypertension, Urology and Vitamin deficiency. The Pharma business operations are supported by various contract manufacturers having facilities which are WHO GMP Compliant. The core strength lies in getting approved formulation manufactured through contract manufacturers under loan licence and marketing of formulations through marketing network across geographies.The product portfolio consists of 429 products, as on January 31, 2023. The Company has business to business supply agreements with 58 domestic distributors and 139 international distributors for distribution and/or contract manufacturing supply. The Company is proposing an initial public issue consisting of upto 388000 Equity Shares through Fresh Issue.